224 related articles for article (PubMed ID: 31393666)
41. A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.
Stiles AR; Zhang H; Dai J; McCaw P; Beasley J; Rehder C; Koeberl DD; McDonald M; Bali DS; Young SP
Mol Genet Metab; 2020 Jul; 130(3):209-214. PubMed ID: 32418857
[TBL] [Abstract][Full Text] [Related]
42. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease.
Lukas J; Giese AK; Markoff A; Grittner U; Kolodny E; Mascher H; Lackner KJ; Meyer W; Wree P; Saviouk V; Rolfs A
PLoS Genet; 2013; 9(8):e1003632. PubMed ID: 23935525
[TBL] [Abstract][Full Text] [Related]
43. Identification of a novel loss-of-function mutation of the GLA gene in a Chinese Han family with Fabry disease.
Zhou C; Huang J; Cui G; Zeng H; Wang DW; Zhou Q
BMC Med Genet; 2018 Dec; 19(1):219. PubMed ID: 30587147
[TBL] [Abstract][Full Text] [Related]
44. The D313Y variant in the GLA gene - no evidence of a pathogenic role in Fabry disease.
Hasholt L; Ballegaard M; Bundgaard H; Christiansen M; Law I; Lund AM; Norremolle A; Krogh Rasmussen A; Ravn K; Tumer Z; Wibrand F; Feldt-Rasmussen U
Scand J Clin Lab Invest; 2017 Dec; 77(8):617-621. PubMed ID: 29037082
[TBL] [Abstract][Full Text] [Related]
45. Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human α-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants.
Yu Y; Mena-Barragán T; Higaki K; Johnson JL; Drury JE; Lieberman RL; Nakasone N; Ninomiya H; Tsukimura T; Sakuraba H; Suzuki Y; Nanba E; Mellet CO; García Fernández JM; Ohno K
ACS Chem Biol; 2014 Jul; 9(7):1460-9. PubMed ID: 24783948
[TBL] [Abstract][Full Text] [Related]
46. Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease.
Shiozuka C; Taguchi A; Matsuda J; Noguchi Y; Kunieda T; Uchio-Yamada K; Yoshioka H; Hamanaka R; Yano S; Yokoyama S; Mannen K; Kulkarni AB; Furukawa K; Ishii S
J Biochem; 2011 Feb; 149(2):161-70. PubMed ID: 20961863
[TBL] [Abstract][Full Text] [Related]
47. Baseline Characteristics of Fabry Disease "Amenable" Migalastat Patients in Argentinian Cohort.
Jaurretche S; Alonso S; Calvo M; Fernandez S; Figueredo H; Galli B; Marin I; Martinez A; Mattausch S; Perretta F; Politei J; Rolon JI; Calabrese E
Glob Health Epidemiol Genom; 2024; 2024():9293896. PubMed ID: 38410281
[TBL] [Abstract][Full Text] [Related]
48. Migalastat Treatment in a Kidney-Transplanted Patient with Fabry Disease and N215S Mutation: The First Case Report.
Di Stefano V; Mancarella M; Camporeale A; Regalia A; Ferraresi M; Pisaniello M; Cassinerio E; Pieruzzi F; Motta I
Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959703
[TBL] [Abstract][Full Text] [Related]
49. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene.
Ferri L; Guido C; la Marca G; Malvagia S; Cavicchi C; Fiumara A; Barone R; Parini R; Antuzzi D; Feliciani C; Zampetti A; Manna R; Giglio S; Della Valle CM; Wu X; Valenzano KJ; Benjamin R; Donati MA; Guerrini R; Genuardi M; Morrone A
Clin Genet; 2012 Mar; 81(3):224-33. PubMed ID: 21517827
[TBL] [Abstract][Full Text] [Related]
50. Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease.
Lukas J; Scalia S; Eichler S; Pockrandt AM; Dehn N; Cozma C; Giese AK; Rolfs A
Hum Mutat; 2016 Jan; 37(1):43-51. PubMed ID: 26415523
[TBL] [Abstract][Full Text] [Related]
51. Treatment of fabry disease: current and emerging strategies.
Rozenfeld P; Neumann PM
Curr Pharm Biotechnol; 2011 Jun; 12(6):916-22. PubMed ID: 21235448
[TBL] [Abstract][Full Text] [Related]
52. Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone.
Shin SH; Kluepfel-Stahl S; Cooney AM; Kaneski CR; Quirk JM; Schiffmann R; Brady RO; Murray GJ
Pharmacogenet Genomics; 2008 Sep; 18(9):773-80. PubMed ID: 18698230
[TBL] [Abstract][Full Text] [Related]
53. α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.
Siekierska A; De Baets G; Reumers J; Gallardo R; Rudyak S; Broersen K; Couceiro J; Van Durme J; Schymkowitz J; Rousseau F
J Biol Chem; 2012 Aug; 287(34):28386-97. PubMed ID: 22773828
[TBL] [Abstract][Full Text] [Related]
54. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.
Yasuda M; Shabbeer J; Benson SD; Maire I; Burnett RM; Desnick RJ
Hum Mutat; 2003 Dec; 22(6):486-92. PubMed ID: 14635108
[TBL] [Abstract][Full Text] [Related]
55. A case of latent heterozygous Fabry disease in a female living kidney donor candidate.
Minami M; Mizuma E; Nakahara M; Oda Y; Yoshimine H; Tokunaga K; Mitsuke A; Yamada Y; Enokida H; Masutani K; Goto N; Ido A
CEN Case Rep; 2021 Feb; 10(1):30-34. PubMed ID: 32712909
[TBL] [Abstract][Full Text] [Related]
56. A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry's Disease.
Majid H; Verma N; Bhandari S; Gupta S; Nidhi
Expert Opin Pharmacother; 2024 Apr; 25(6):769-782. PubMed ID: 38753367
[TBL] [Abstract][Full Text] [Related]
57. Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants.
Yam GH; Bosshard N; Zuber C; Steinmann B; Roth J
Am J Physiol Cell Physiol; 2006 Apr; 290(4):C1076-82. PubMed ID: 16531566
[TBL] [Abstract][Full Text] [Related]
58. Fabry disease biomarkers in patients switched from enzyme-replacement therapy to migalastat oral chaperone therapy.
Auray-Blais C; Lavoie P; Martineau T; Ntumba GK; Gamrani M; Khan A; Altarescu G; Lehman A; Goker-Alpan O; Nowak A; West ML; Bichet DG
Bioanalysis; 2023 Dec; 15(23):1421-1437. PubMed ID: 37847061
[No Abstract] [Full Text] [Related]
59. Pharmacological chaperone therapy for Fabry disease.
Ishii S
Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(1):18-30. PubMed ID: 22241068
[TBL] [Abstract][Full Text] [Related]
60. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease.
Khanna R; Soska R; Lun Y; Feng J; Frascella M; Young B; Brignol N; Pellegrino L; Sitaraman SA; Desnick RJ; Benjamin ER; Lockhart DJ; Valenzano KJ
Mol Ther; 2010 Jan; 18(1):23-33. PubMed ID: 19773742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
